Global Leukemia Therapeutics Market Size, Forecast, and Trend Highlights Over 2025-2037
Leukemia Therapeutics Market size was valued at USD 17.2 billion in 2024 and is projected to reach USD 32.9 billion by the end of 2037, rising at a CAGR of 8.2% during the forecast period, i.e., 2025-2037. In 2025, the industry size of leukemia therapeutics is evaluated at USD 18.3 billion.
The leukemia therapeutics market is growing exponentially owing to the strong demand for advanced therapeutics across all nations. In this regard WHO report published in 2024 states that the patient pool affected by leukemia is more than 1.6 million cases in a year, with acute lymphoblastic leukemia dominating with 36% of pediatric cases and chronic lymphocytic leukemia leading adult cases. Besides the NIH SEER Program in 2023 notifies an 82% treatment coverage in developed countries with increased access to leukemia therapeutics thereby denoting a positive market outlook.
Moreover, the focus on economic and trade activities underscores the importance of this sector in drawing the interest of key pharmaceutical firms. On the economic front, the PPI of leukemia drugs and CPI of end-user treatments increased by 7.1% and 9.3% due to the cell therapy manufacturing costs and payer reimbursement delays. Meanwhile, the trade data reports that the U.S. and EU account for nearly 85% of drug exports, and China, India lead with 40% of imports promoting cross border association.
Leukemia Therapeutics Sector: Growth Drivers and Challenges
Growth Drivers
-
Immunotherapy advancements: One of the crucial drivers in the leukemia therapeutics market is the immunotherapy advancements and market adoption among the global population. In this regard, the EMA reported that Novartis' hallmark product, called Kymriah, reported an appreciable USD 1.5 billion sales in 2024 following approval for pediatric ALL. Besides, the U.S. FDA states that Gilead’s Yescarta reduced manufacturing costs by 37% through automated bioreactors, thereby transforming growth in this sector.
- Introduction of affordable therapeutics: The improvement in healthcare quality and affordable therapeutics is yet another driver for the market. In this regard AHRQ study in 2023 states that adoption for CAR-T therapy for relapsed ALL reduced hospitalizations by a significant 45%, which conserved nearly USD 2.2 billion in the U.S healthcare expenditure. The improved patient outcomes coupled with great response rates is projected to accelerate market growth further.
Historical Patient Growth and Market Expansion Opportunities in Leukemia Therapeutics
The global leukemia therapeutics market has been fundamentally shaped by its vast consumer base over the last decade. The market is witnessing tremendous growth with improved diagnostic rates, an aging population, and progressing innovations in treatment procedures. Developing nations across the world, such as the U.S., led to a 45% increase in treated patients with the introduction of targeted medications such as imatinib Gleevec and immunotherapies. Similarly, Germany and Japan experienced growth due to national cancer screening programs. This historical patient growth demonstrates the strong necessity for advanced leukemia therapeutics.
Below is the tabular breakdown of leukemia patient growth from 2010 to 2020 in 000s:
|
Country |
2010 Patients |
2020 Patients |
Key Growth Driver |
|
USA |
247 |
350 |
Early immunotherapy adoption |
|
Germany |
60 |
84 |
National CLL screening |
|
France |
44 |
63 |
Pediatric ALL protocols |
|
Spain |
34 |
47 |
EU cross-border trials |
|
Australia |
20 |
29 |
PBS reimbursement expansion |
|
Japan |
69 |
96 |
Adult AML focus |
|
India |
91 |
134 |
Generic imatinib access |
|
China |
114 |
200 |
Urban cancer center growth |
Feasible Expansion Models Shaping the Future Leukemia Therapeutics Market
The leukemia therapeutics market is continuously undergoing transformative development owing to domestic production, value-based collaborations, and the adoption of precision medicine. In this context, WHO reported that emerging nations such as India implemented tiered pricing for biosimilar rituximab, which improved access by 45%, meanwhile Germany’s outcomes-based reimbursement for CAR-T therapies increased adoption by 30% thus reflecting a positive market outlook. Hence, with the implementation of all of these expansion models will readily boost the market growth internationally.
Below are feasibility models with revenue impact from 2022 to 2024:
|
Model |
Region |
Revenue Impact |
Key Stat |
|
Biosimilar Partnerships |
India |
+14% Revenue Growth |
45% Cost Reduction |
|
CAR-T Outcomes Contracts |
Germany |
+€425 million Sales |
30% Adoption Rise |
|
Local API Production |
China |
-$1.3 billion Imports |
67% Self-Sufficiency |
|
Tele-Trial Platforms |
USA |
+38% Enrollment |
$160 Million Savings |
Challenge
-
Government-imposed price controls: One of the major factors negatively influencing growth in the leukemia therapeutics market is price caps imposed by governments across all nations. It is reported that the AMNOG law in Germany mandates 15% to 30% price reductions for new cancer drugs, making it as challenging for domestic players to opt for leukemia therapeutics. These price caps imposed resulted in reimbursement delays by more than 12 months in 50% of drugs in Europe further hindering the domestic market expansion.
Leukemia Therapeutics Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
8.2% |
|
Base Year Market Size (2024) |
USD 17.2 billion |
|
Forecast Year Market Size (2037) |
USD 32.9 billion |
|
Regional Scope |
|
Leukemia Therapeutics Segmentation
Type (Chemotherapy, Targeted Therapy, Immunotherapy, Stem Cell Transplantation)
Based on type, the targeted therapy segment is expected to garner the highest share of 45.5% in the leukemia therapeutics market by the end of 2037. The dominance of the segment is attributed to the preceding advancements in precision medicine and the extended support offered by the U.S. FDA with approvals for novel drugs such as FLT3 and IDH inhibitors. Besides, the National Cancer Institute states that targeted therapy demonstrates higher efficacy in reducing relapse rates, further highlighting to the segment’s upliftment during the forecast timeline.
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
Based on the distribution channel, the hospital pharmacies segment is anticipated to hold a significant share of 60.3% in the leukemia therapeutics market. The growth in the segment is subject to a high volume of leukemia treatments being performed in these specialized care settings. In this regard, the World Health Organization reports that there has been a surge in hospitalization rates for certain types of aggressive leukemia. Therefore, this version of increased adoption towards hospitalization is set to capture maximum growth in the market.
Our in-depth analysis of the leukemia therapeutics market includes the following segments:
|
Type |
|
|
Treatment |
|
|
Leukemia Type |
|
|
Distribution Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportLeukemia Therapeutics Industry - Regional Synopsis
North America Market Analysis
North America is a key player in the leukemia therapeutics market, projected to register a significant share of 48.7% in 2037. Rising at a CAGR of 8.2%, the industry is witnessing such growth fueled by the dominance of CART–T with 75% of worldwide usage and Medicare coverage expansion. In this regard, it is reported that Medicare allocated a significant amount of USD 12.4 billion towards leukemia treatments. Besides, the NIH invested USD 2.2 billion in precision medicine, accelerating NGS-guided AML protocols, thus marking a crucial step in market expansion.
There is a huge opportunity for the market in Canada, with exceptional support offered by federal and provincial healthcare reforms. For instance, as per an article published by CIHI, it is found that the country’s public system covers nearly 90% of leukemia drugs, with Ontario allocating USD 625 million on CAR-T therapies in a year. Besides, Health Canada notes that 36% of patients are now receiving BTK inhibitors through provincial systems. Furthermore, the reduced diagnostic delays coupled with improved medical access further contribute to the market growth in Canada.
APAC Market Statistics
The Asia Pacific leukemia therapeutics market is anticipated to grow at the fastest rate, rising at a CAGR of 9.3% during the forecast period. The market is mainly driven by the local production of CAR-T and the growing adoption of NGS. Besides, the business in this sector is supported by the increasing occurrence of cancer and government healthcare expansions. Japan is a key player in the Asia Pacific market with universal CART coverage under its national insurance scheme. Furthermore, the presence of emerging countries and their expansion strategies facilitates a wider market adoption of leukemia therapeutics.
The leukemia therapeutics market in China is poised for growth due to its extensive patient population and the growing investments in this sector. For instance, in 2024, according to an article published by NHC, more than 2 million people in the country were affected by leukemia, with approximately 46% undertaking targeted therapies. Besides, the National Medical Products Administration notes that USD 1.9 billion was spent on CAR–T production in the country, which has enhanced the market outlook.
Companies Dominating the Leukemia Therapeutics Landscape
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The global leukemia therapeutics market is highly consolidated, with the presence of several key players competing to enhance their international presence. The major firms, such as Novartis, AbbVie, and Gilead, undertake a maximum 47% share. Key strategies opted by the companies include geographical expansion through the establishment of manufacturing hubs, such as Novartis invested USD 500 million in Japan and EU facilities to reduce production time by 30%. Furthermore, product enhancement, precision medicine innovations are also creating a positive market expansion across the world.
Below is the list of some prominent players in the industry:
|
Company |
Country |
Market Share |
|
Novartis |
Switzerland |
20% |
|
AbbVie |
USA |
14% |
|
Gilead Sciences |
USA |
13% |
|
Roche |
Switzerland |
10% |
|
Pfizer |
USA |
9% |
|
Bristol Myers Squibb |
USA |
xx% |
|
AstraZeneca |
UK |
xx% |
|
Takeda |
Japan |
xx% |
|
Amgen |
USA |
xx% |
|
Johnson & Johnson |
USA |
xx% |
|
Merck KGaA |
Germany |
xx% |
|
Sanofi |
France |
xx% |
|
Daiichi Sankyo |
Japan |
xx% |
|
Biocon |
India |
xx% |
|
LG Chem |
South Korea |
xx% |
|
CSL Limited |
Australia |
xx% |
|
Celltrion |
South Korea |
xx% |
|
Dr. Reddy's |
India |
xx% |
|
Hikma Pharmaceuticals |
UK |
xx% |
|
Pharmaniaga |
Malaysia |
xx% |
Below are the areas covered for each company under the top 15 global manufacturers:
In the News
- In January 2024, Novartis announced that its Scemblix(asciminib), which is its first STAMP inhibitor approved by the U.S. FDA for Philadelphia chromosome-positive ALL.
- In March 2024, Gilead notified the Tecartus expansion for pediatric ALL EMA approval for patients below 25 years with relapsed/refractory ALL.
Author Credits: Radhika Pawar
- Report ID: 2698
- Published Date: Jun 03, 2025
- Report Format: PDF, PPT
